BioSpace News Archive

Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.

Werewolf Therapeutics, Inc. today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.

Stereotaxis announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System.

Scinai Immunotherapeutics Ltd. announced that its primary creditor, the European Investment Bank, is currently considering favorably adjusting the terms of the EIB’s financial facility contract with the Company, in particular by extending the facility’s maturity.

Senti Biosciences, Inc. today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 1-5, 2023, in San Diego, CA.

Complete Genomics announced at the American Society of Human Genetics Annual Meeting, Nov. 1-5, in Washington details on the commercial and technical momentum it has demonstrated in the last 10 months since launching in the United States market through new customers, partnerships and collaborations.

M.S.Q. Ventures is pleased to announce that its client, BioLineRx Ltd., has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. and an associated investor for the development of motixafortide across all indications in Asia.

Coeptis Therapeutics Holdings, Inc. today announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, through combinatorial use of different adaptors will be the subject of a poster presentation at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).

Capstan Therapeutics, Inc. today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer 38th Annual Meeting in San Diego, California.

PacBio (NASDAQ: PACB) today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S rRNA sequencing on PacBio’s long-read sequencing systems to enable large-scale studies at a resolution difficult to attain with short-read RNA sequencing.